The epigenetic silencing of tumor suppressor genes is a common event during carcinogenesis, and often involves aberrant DNA methylation and histone modification of gene regulatory regions, resulting in the formation of a transcriptionally repressive chromatin state. Two examples include the antimetastatic, tumor suppressor genes, desmocollin 3 (DSC3) and MASPIN, which are frequently silenced in this manner in human breast cancer. Treatment of the breast tumor cell lines MDA-MB-231 and UACC 1179 with 5-aza-2 0 -deoxycytidine (5-azaCdR) induced transcriptional reactivation of both genes in a dose-dependent manner. Importantly, DSC3 and MASPIN reactivation was closely and consistently linked with significant decreases in promoter H3 K9 di-methylation. Moreover, 5-aza-CdR treatment also resulted in global decreases in H3 K9 di-methylation, an effect that was linked to its ability to mediate dose-dependent, posttranscriptional decreases in the key enzyme responsible for this epigenetic modification, G9A. Finally, small interfering RNA (siRNA)-mediated knockdown of G9A and DNMT1 led to increased MASPIN expression in MDA-MB-231 cells, to levels that were supra-additive, verifying the importance of these enzymes in maintaining multiple layers of epigenetic repression in breast tumor cells. These results highlight an additional, complimentary mechanism of action for 5-aza-CdR in the reactivation of epigenetically silenced genes, in a manner that is independent of its effects on DNA methylation, further supporting an important role for H3 K9 methylation in the aberrant repression of tumor suppressor genes in human cancer.
Introduction
Epigenetic modifications to DNA and histones serve as a tractable set of switches crucial to normal cellular differentiation and proper organism development, regulating gene expression, X chromosome inactivation, genomic imprinting and chromosomal stability (Jaenisch and Bird, 2003) . Abnormal alterations to the epigenome have been implicated in a number of human diseases such as cancer, autoimmune syndromes and psychiatric and behavioral disorders (Huang et al., 2003) . The plasticity and variety of epigenetic modifications, however, also represent an encouraging array of therapeutic targets that can be altered pharmacologically to reprogram irregular epigenetic profiles.
5-Methylcytosine is an epigenetic mark that is strongly associated with transcriptional repression when elevated levels of this modified base are present in CpGdense islands that encompass upstream gene regulatory regions (Baylin et al., 1998; Jones and Takai, 2001 ). An important means by which DNA hypermethylation within these regions suppresses gene expression is through an indirect mechanism, by virtue of its ability to attract protein complexes that alter the modification profile of its associated histones to drive the formation of transcriptionally incompetent heterochromatin (Boyes and Bird, 1991; Jones et al., 1998; Robertson et al., 2000) . Consistent with this idea, increasing evidence has revealed that cytosine methylation often co-exists with repressive histone H3 K9 methylation, due to the ability of DNA methyltransferases and the methyl-CgG-binding protein, MECP2, to recruit histone H3 K9-specific methyltransferase activity (Fuks et al., 2003a, b) . Notably, H3 K9 can be mono-, di-or trimethylated, with various degrees of methylation being associated with discrete, condensed regions of the genome. It appears that H3 K9 mono-and di-methylation are reserved for transcriptionally suppressed regions of euchromatin and are deposited by the histone methyltransferase G9A, while tri-methylation is prevalent in pericentric heterochromatin domains, primarily from the activity of the SUV39H1 and SUV39H2 histone methyltransferases (Peters et al., 2003; Rice et al., 2003) . Of clinical relevance, aberrant DNA and histone H3 K9 hypermethylation have also been linked to the silencing of a number of critical tumor suppressor genes during neoplastic progression (Baylin et al., 1986; Gonzalez-Zulueta et al., 1995; Kondo et al., 2003) , making these epigenetic modifications ideal targets for pharmacologic intervention in cancer patients.
5-aza-CdR is a nucleoside antimetabolite originally synthesized over 40 years ago (Pliml and Sorm, 1964) . Since then, numerous mechanistic studies revealed that 5-aza-CdR is a potent inhibitor of DNA methyltransferase (DNMT) activity, through irreversible binding of DNMTs to 5-aza-CdR-substituted DNA (Creusot et al., 1982) . The ability of 5-aza-CdR to sequester DNMTs and inhibit their function appears to have differential effects on tumor cells in vitro, in a manner that is dosedependent. At high doses, 5-aza-CdR is cytotoxic to cancer cells, via the formation of covalent DNA adducts and obstruction of DNA synthesis (Michalowsky and Jones, 1987; Juttermann et al., 1994) . Meanwhile, lower, subtoxic doses of 5-aza-CdR have been shown to initiate reductions in 5-methylcytosine levels both globally (Creusot et al., 1982) , as well as locally, in the CpGdense regulatory regions of a number of epigenetically silenced tumor suppressor genes, leading to their reactivation (Otterson et al., 1995; Herman et al., 1998; Bovenzi and Momparler, 2001; Oue et al., 2001; Koul et al., 2002) . The non-cytotoxic, DNA hypomethylating effects of 5-aza-CdR have also been associated with differentiation and growth inhibition of tumor cells through cell-cycle arrest and/or apoptosis (Momparler et al., 1985; Bender et al., 1998; Hsi et al., 2005) , enhancing interest in this drug as an anticancer agent.
Early clinical studies sought to take advantage of the cytotoxic properties of high-dose 5-aza-CdR in an attempt to treat various neoplastic diseases in humans, with some encouraging results in hematologic malignancies; however, solid tumors have been largely refractory to such treatments (Santini et al., 2001) . In light of growing support for the role that epigenetic gene inactivation plays in tumorigenesis, recent trials have focused on lower-dose, longer duration treatment schedules, in an effort to exploit the DNA demethylation and tumor differentiation effects of 5-aza-CdR in cancer patients (Kantarjian and Issa, 2005; Rosenfeld, 2005) . These new dosing regimens have been generally well tolerated and have produced favorable results in patients with various hematopoietic cancers, with many seeing significant clinical improvement and/or complete remission (Wijermans et al., 2000; Lubbert et al., 2001; Kantarjian et al., 2003; Issa et al., 2004) . Of interest, these studies also reported that patient responses were slow to develop, typically requiring three cycles of treatment for best results, implying that a more prolonged, subtoxic 5-aza-CdR treatment schedule induces its antiproliferative effects via an alternative, non-cytotoxic mechanism of action. This notion has garnered further support from other clinical investigations demonstrating that low-dose 5-aza-CdR treatment results in both global and promoter-specific decreases in DNA methylation in patients with myelodysplasia, and also in those with intractable solid tumors (Daskalakis et al., 2002; Mund et al., 2005; Samlowski et al., 2005) . In total, these results using low-dose, more frequent 5-aza-CdR administration provide compelling evidence for its continued optimization and use as a DNA hypomethylating agent in the treatment of a wide range of tumor types.
Although the cytotoxic and DNA demethylation capabilities of 5-aza-CdR have been well characterized both in vitro and in vivo, there is also reason to believe that this drug may exhibit alternative mechanisms of action with regard to transcriptional reactivation. For example, 5-aza-CdR can induce expression of genes lacking CpG methylation, such as p21WAF1, CDKN2D and APAF-1 (Soengas et al., 2001; Zhu et al., 2001; Scott et al., 2006) . Consistent with the idea that 5-azaCdR has additional modes of action, recent work indicates that 5-aza-CdR treatment is associated with histone H3 K9 demethylation in the regulatory regions of silenced genes (Fahrner et al., 2002; Nguyen et al., 2002; Coombes et al., 2003) . Nonetheless, a detailed comparison of the extent and relative importance of DNA demethylation and H3 K9 demethylation mediated by 5-aza-CdR has not been conducted for genes harboring high levels of both modifications. Additionally, the mechanism by which 5-aza-CdR potentiates reductions in H3 K9 methylation has not been previously identified. The aims of this study, therefore, were to analyse the relative contributions of DNA and histone H3 K9 methylation reversal to the reactivation of epigenetically silenced genes in breast tumor cells, and also to elucidate the mechanism by which 5-aza-CdR alters H3 K9 methylation levels.
To this end, we analysed the effects of 5-aza-CdR on DNA and histone H3 K9 di-methylation in the promoter regions of two antimetastatic, tumor suppressor genes, DSC3 and MASPIN, which are aberrantly silenced in a significant fraction of breast tumors via epigenetic mechanisms (Domann et al., 2000; Futscher et al., 2004; Oshiro et al., 2005) . We show here that the ability of 5-aza-CdR to reactivate this class of genes in MDA-MB-231 and UACC 1179 breast tumor cells is consistent with reductions in H3 K9 di-methylation to the levels seen in DSC3-and MASPIN-positive normal mammary epithelial cells (HMECs), even in the absence of significant DNA demethylation in some cases. Furthermore, the ability of 5-aza-CdR to inhibit H3 K9 methylation in these breast cancer cell lines was closely linked to post-treatment reductions in G9A histone methyltransferase protein levels that were not due to effects on G9A gene expression. Finally, transfection of breast tumor cells with G9A-and/or DNMT1-specific small interfering RNA (siRNA) led to increases in MASPIN expression, and verified the importance of these enzymes in the cooperative epigenetic silencing of this gene, both of which are also inhibited by 5-aza-CdR. In summary, these results indicate that while aberrant DNA methylation and repressive histone modifications work in combination to silence many important tumor suppressor genes in human cancers, 5-aza-CdR can act at both levels, either singly or concomitantly, to reactivate expression of such genes in a manner that is cell type-and loci-specific.
Results
The DSC3 and MASPIN promoters both contain CpG islands (Figure 1 ) that are subject to epigenetic silencing in a large percentage of human breast cancers (Domann et al., 2000; Oshiro et al., 2005) , although it should be noted that the MASPIN promoter is considered a marginal CpG island. More specifically, while the DSC3 and MASPIN promoters are both considered CpG islands by the earlier, less stringent criteria of GardinerGarden and Frommer (1987) , only DSC3 meets the more recent, rigorous criteria of Takai and Jones (2002) . Given the importance of the DSC3 and MASPIN proteins in restricting epithelial cell motility/invasion and maintaining proper tissue architecture, these genes represent ideal candidates for pharmacologic interventions aimed at transcriptional reactivation in tumors and antimetastases effects.
To better understand the epigenetic regulation of DSC3 and MASPIN, two breast epithelial tumor cell lines, MDA-MB-231 and UACC 1179, were treated with increasing doses of the DNA methyltransferase inhibitor, 5-aza-CdR. Real-time reverse transcriptionpolymerase chain reaction (RT-PCR) analysis of DSC3 and MASPIN expression levels revealed that treatment with 5-aza-CdR did reactivate transcription of these genes in both tumor cell lines, in a dose-dependent manner (Figure 2a and b) . However, while the degree of DSC3 and MASPIN re-expression in MDA-MB-231 cells peaked at the highest dose of 5-aza-CdR administered (10 mM), in UACC 1179 cells, the greatest levels of transcriptional reactivation occurred following a dose of 3 mM 5-aza-CdR. These results further support the idea that the epigenetic silencing of genes such as DSC3 and MASPIN is reversible through the use of pharmacologic inhibitors of enzymes that catalyse repressive epigenetic modifications.
In an effort to determine whether 5-aza-CdR initiates tumor suppressor gene reactivation from the same CpG island-associated transcription start site as that utilized basally, or whether cryptic upstream sites became active, 5 0 rapid amplification of cDNA ends (RACE) was performed. Total RNA from MASPIN-positive, normal HMECs, as well as from MDA-MB-231 and UACC 1179 breast tumor cells treated with 5-aza-CdR was converted to cDNA and amplified using primers specific for the 5 0 end of the predicted MASPIN transcript. For all samples, MASPIN-specific 5 0 RACE PCR produced amplicons of similar size (Figure 2c ), suggesting that all transcripts are initiated from the same region of the MASPIN promoter, whether constitutively expressed in HMECs or 5-aza-CdR-induced in breast cancer cells. Subsequent cloning and sequencing of the MASPIN 5 0 RACE PCR products confirmed that 5-aza-CdR was not activating a distant, alternative start site, as the 5 0 end of all MASPIN transcripts were mapped to the same localized, CpG island-embedded domain centered around the predicted start site (Supplementary Figure 1) . Furthermore, it was determined that MAS-PIN transcription is not initiated from a single start site in either normal HMECs or 5-aza-CdR-treated breast cancer cells, but rather from multiple start sites within this B75 bp region (Supplementary Figure 1) . The variation in MASPIN transcription start sites observed both basally in HMECs and after 5-aza-CdR treatment in breast tumor cells is consistent with the flexible nature of transcriptional initiation seen in TATA-less promoters, such as the MASPIN gene (Smale, 1997; Suzuki et al., 2001) .
As 5-aza-CdR is capable of inducing re-expression of DSC3 and MASPIN in MDA-MB-231 and UACC 1179 breast tumor cells (Oshiro et al., 2003) , we set out to determine its effects on cytosine methylation levels in the promoter regions of both genes, immediately upstream of transcription start. Our breast tumor cell lines were treated once again with a high dose of 5-aza-CdR (10 mM), followed by extensive sodium bisulfite sequencing of the DSC3 and MASPIN promoters. For this analysis, we compiled sequence data from 94 clones for each gene-associated CpG island in both cell lines, examining the methylation status of 24 CpG sites in the DSC3 promoter and 19 CpG sites in the MASPIN promoter (Figure 1 ). The percentage of methylation at each CpG site in the promoters of these genes was then calculated, as well as the percentage of methylation across the regions as a whole. Statistical significance of 5-aza-CdR treatment on DNA methylation was assessed using a two-sample test of proportions, comparing the percentage of methylated sites over the entire promoter region analysed, before and after treatment. The P-value obtained was then tested at the 95% confidence level (Pvalue p0.05 were considered statistically significant), to determine whether or not significant changes in regional DNA methylation had occurred following 5-aza-CdR treatment in the DSC3 and MASPIN promoters in both cell lines.
Methylation analysis of the DSC3 promoter in MDA-MB-231 cells revealed a statistically significant reduction in regional promoter methylation after DNA methyltransferase inhibition, decreasing from 79.6 to 54.9% overall (*P-value o0.0001), along with the increasing Gene reactivation via 5-aza-CdR-mediated reductions in G9A RJ Wozniak et al emergence of completely 'naked' alleles ( Figure 3a) . Conversely, in UACC 1179 cells, DSC3 promoter methylation was not significantly reduced following 5-aza-CdR treatment (P-value ¼ 0.2911) (Figure 3a) . It is interesting to note, however, that the DSC3 gene in MDA-MB-231 cells, which experienced the greatest degree of promoter demethylation following 5-aza-CdR treatment, also exhibited the largest increase in gene reactivation (Figure 2a, left) . For the MASPIN CpG island promoter, we found that 5-aza-CdR treatment also failed to significantly alter regional methylation of this promoter in either MDA-MB-231 or UACC 1179 cells (P-values ¼ 0.2370 and 0.8593, respectively) ( Figure 3b ). Despite the lack of a statistically significant decrease in methylation of some of the CpG island promoters, it is possible that gene reactivation occurs from the few alleles that become demethylated in the cell populations.
Taken together, these data indicate that while 5-azaCdR can, in some contexts, reduce cytosine methylation at select loci, the cellular and loci-specific effects of this drug on gene reactivation are likely not limited to DNA demethylation, suggesting that other epigenetic modifications may also be targeted by 5-aza-CdR.
The epigenetic silencing of genes can result from modifications to both DNA and histones in regions of transcriptional regulation. In light of our data above, showing increased expression of DSC3 and MASPIN following 5-aza-CdR treatment in the absence of consistent promoter DNA demethylation, we sought to investigate additional mechanisms of action for this drug at the histone level. Two of the most widely studied histone modifications include the acetylation of lysine residues on histones H3 and H4, and the methylation of lysine 9 on histone H3. Acetylation of histones H3 and H4 leads to a transcriptionally permissive chromatin RACE PCR products were run on a 3% agarose gel (shown above) for size determination (predicted size: B275 bp) before PCR product cloning and DNA sequencing. As a negative control, the same 5 0 RACE protocol was also performed without template RNA (NTC ¼ no template control).
state, thus, it is not surprising that both the DSC3 and MASPIN promoters contain underacetylated histones in MDA-MB-231 and UACC 1179 cells (Oshiro et al., 2003) . However, following 5-aza-CdR treatment, histone acetylation was not markedly increased in either the DSC3 or MASPIN promoters in MDA-MB-231 cells (data not shown). Conversely, elevated levels of histone H3 K9 di-methylation in the promoter regions of genes is highly correlated with transcriptional repression (Nielsen et al., 2001) and is also involved in X-chromosome inactivation (Heard et al., 2001) . As the H3 K9 methylation status of the DSC3 and MASPIN promoters has not previously been reported for our breast tumor cell lines, we wanted to examine the extent of H3 K9 di-methylation in these promoters in MDA-MB-231 and UACC 1179 cells, and also to measure the effects of 5-aza-CdR on this repressive histone methylation mark.
DSC3 and MASPIN are expressed in a variety of normal epithelial tissues, but are not expressed in tissues of mesenchymal origin (Koch and Franke, 1994; Futscher et al., 2002) . To determine whether inactivation of the DSC3 and MASPIN genes in human epithelial breast cancer strains and normal fibroblastic cells is associated with elevations in repressive histone methylation, we compared the basal levels of H3 K9 dimethylation in the promoters of these genes in normal and tumor cell lines with known expression status. To this end, we analysed HMECs, which are DSC3-and MASPIN-positive, along with human foreskin fibroblasts (HFFs) and MDA-MB-231 and UACC 1179 breast tumor cells, which are all DSC3-and MASPINnegative (see Figure 2a and b). Chromatin immunoprecipitations (ChIP) were performed using an antibody against di-methyl H3 K9, followed by real-time PCR amplification with gene-specific primers to quantitate the degree of H3 K9 methylation in the DSC3, MASPIN and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoters (Figure 4a ). In HMECs, where both genes are highly expressed, H3 K9 di-methylation of their promoter regions was minimal, with both having very low levels of detectable di-methyl H3 K9 (B9% of their respective input amounts). Conversely, in HFFs, the promoters of the DSC3 and MASPIN genes had 7-10-fold higher H3 K9 di-methylation levels (66 and 91% of their input DNAs, respectively), consistent a b Figure 3 Methylation status of 94 sequenced clones (47 each from two biological replicates), analysing 24 and 19 CpG sites in the DSC3 and MASPIN promoters, respectively, before and after a 96 h treatment with 10 mM 5-aza-CdR. In these diagrams, each row represents one cloned PCR product, whereas the columns contain the data for each of the CpG sites analysed (' methylated sites, & unmethylated sites, poor sequence data). Clones were sorted from least to most methylated for presentation. The P-values shown below the graphs of treated samples indicate whether or not any differences in regional methylation following treatment were statistically significant (*) (see text). with their transcriptionally silent state. In comparison, in the DSC3-and ASPIN-negative breast cancer cell lines MDA-MB-231 and UACC 1179, H3 K9 dimethylation was greatly elevated in the same regions of both genes, closely resembling the levels seen in HFFs. As a control, H3 K9 methylation analysis of the GAPDH promoter was also conducted, because this house-keeping gene is ubiquitously expressed in all of the above cell lines and the CpG sites in its promoter are completely unmethylated in all cell types. As expected, minimal levels of this repressive histone modification were detected in the GAPDH promoter in each of our normal and tumor cell lines (from 3 to 15% of their respective inputs), similar to the levels seen for the DSC3 and MASPIN promoters in HMECs.
As the levels of H3 K9 di-methylation in the DSC3 and MASPIN CpG island promoters were found to be elevated in our breast tumor cell lines, in comparison to normal HMECs, untreated tumor cells and those treated with 3 and 10 mM 5-aza-CdR were analysed by di-methyl H3 K9 ChIP, as above (Figure 4b ). The doses of 5-azaCdR used in these analyses were chosen because they resulted in the greatest levels of DSC3 and MASPIN transcriptional reactivation (Figure 2a and b) . In MDA-MB-231 cells, H3 K9 di-methylation levels in the DSC3 promoter decreased significantly in a dose-dependent manner, from 66% of input DNA, to 21 and 10% of input after 3 and 10 mM 5-aza-CdR treatments, respectively. In the same cell line, we also report similar reductions in H3 K9 di-methylation levels in the MASPIN promoter, from 72% of input before treatment to 22% with 3 mM and 11% with 10 mM 5-aza-CdR addition. These experiments were extended to UACC 1179 cells and similar results were seen for both genes, where 2-3-fold decreases in H3 K9 di-methylation occurred after 5-aza-CdR treatment. Meanwhile, the ubiquitously expressed GAPDH gene had consistently low levels of this repressive histone methylation mark, with no 5-aza-CdR effect seen in either tumor cell line. In conclusion, while DNA methylation was not consistently reduced in the silenced DSC3 and GAPDH promoters in our breast tumor cell lines following 5-azaCdR treatment, histone H3 K9 di-methylation was significantly diminished in all cases and closely linked with gene reactivation. These results suggest an additional mechanism by which 5-aza-CdR acts to reverse the epigenetic inactivation of DSC3 and MASPIN in breast tumor cells, via its ability to reduce repressive histone H3 K9 di-methylation in a manner that does not necessarily require concurrent DNA demethylation.
Although 5-aza-CdR has shown its utility as a DNA hypomethylating drug by both clinicians and researchers seeking to reactivate epigenetically silenced genes in human cancers (Otterson et al., 1995; Herman et al., 1998; Daskalakis et al., 2002; Samlowski et al., 2005) , it appears from our data that the cytosine demethylation effects of this drug may be cell type-and loci-specific. Therefore, as the DSC3 and MASPIN promoters in MDA-MB-231 and UACC 1179 cells did not experience significant cytosine demethylation in all cases after 5-aza-CdR treatment, we sought to investigate the global effects of this drug in these cell strains. Genomic DNA digested to individual nucleosides was analysed by liquid chromatography-mass spectrometry (LC-MS) to quantitate 5-methylcytosine levels in our breast tumor cells, before and after treatment with 3 and 10 mM 5-aza-CdR. In MDA-MB-231 cells, total 5-methylcytosine content was reduced by B65% after treatment with 3 and 10 mM 5-aza-CdR (Figure 5a ). Similarly, in UACC 1179 cells, the percentage of cytosines that were methylated decreased by B50-60% after treatment (Figure 5a ). Therefore, despite the ability of 5-aza-CdR to induce global CpG demethylation, the 5-methylcytosine levels in the DSC3 and MASPIN promoters in our breast tumor cells were not consistently decreased in all cases, suggesting that the ability of 5-aza-CdR to demethylate specific regulatory regions is context-dependent, and perhaps explains the fact that 35-50% of the original methylcytosine pool in our cells remained methylated after treatment (Figure 5a) .
As a follow-up to initial studies analysing the effects of H3 K9 di-methylation at select loci, more recent investigations using global array strategies have found H3 K9 methylation to be highly correlated with heterochromatin formation in a number of gene regulatory regions in both normal and tumor cells, leading to transcriptional silencing (Kondo et al., 2004; Miao and Natarajan, 2005) . These reports illustrate the prevalence of this repressive histone modification as a means of epigenetic gene inactivation and suggest that many repressed genes may be amenable to 5-aza-CdRmediated H3 K9 demethylation, similar to the results reported here for the DSC3 and MASPIN genes in our breast tumor cell lines. To investigate the extent of 5-aza-CdR-mediated H3 K9 demethylation in the genome as a whole, Western blots were performed using protein isolated from untreated MDA-MB-231 and UACC 1179 cells, in addition to those treated with 3 and 10 mM doses of 5-aza-CdR. Immunoblots probed with di-methyl H3 K9 antibody show the ability of 5-aza-CdR to promote significant reductions in global H3 K9 di-methylation in MDA-MB-231 cells, with the levels of this histone modification decreasing by 56% following a dose of 3 mM and by 70% following a dose of 10 mM, compared to untreated cells (Figure 5b ). Similar decreases in genome-wide H3 K9 di-methylation were also witnessed in UACC 1179 cells after treatment with the same doses of 5-aza-CdR (Figure 5b ). The data from these Western blots reveal the ability of 5-aza-CdR to initiate H3 K9 demethylation throughout the genome, not simply at select loci, implying that 5-aza-CdR may have wideranging effects on global expression and chromatin architecture through depletion of this repressive histone modification. Next, we sought to determine whether 5-aza-CdR treatment had any effect on global levels of G9A, the histone methyltransferase primarily responsible for H3 K9 di-methylation of gene promoter regions. To this end, whole-cell protein lysates were probed for G9A protein levels via Western blot, before and after treatment with increasing doses of 5-aza-CdR. The results of this investigation revealed that 5-aza-CdR treatment of MDA-MB-231 and UACC 1179 cells led to dose-dependent reductions in whole-cell G9A protein levels, with the highest doses (3 and 10 mM) resulting in 70-76% decreases overall, in both cell lines (Figure 6a ). Over the same dosing range, we did not see reduced levels of G9A transcript levels in either cell line following quantitative RT-PCR analysis of G9A expression (Figure 6b ), implying that 5-aza-CdR-mediated decreases in G9A protein levels are likely initiated posttranscriptionally. Although the precise mechanism of post-transcriptional G9A degradation following 5-azaCdR treatment is currently unknown, these decreases in cellular G9A levels post-treatment are consistent with the ability of 5-aza-CdR to reactivate epigenetically silenced genes via demethylation of the K9 residue on histones H3 in the promoters of such genes. Of note, basal G9A transcript levels in these untreated tumor cell lines are approximately 4.5-fold higher than those seen in our reference cell line, normal HMECs (Figure 6b) , and may therefore account for the aberrant silencing of tumor suppressor genes in epithelial tumors of the breast via increases in promoter H3 K9 di-methylation. Finally, RT-PCR quantitation of another H3 K9-specific methyltransferase, SUV39H1, revealed no decreases in its expression in breast tumor cells following treatment with 5-aza-CdR (Supplementary Figure 2) .
Our data here implicate both DNA hypermethylation and elevated histone H3 K9 di-methylation in the silencing of tumor suppressor genes in breast cancer, and suggest that 5-aza-CdR can reduce both to varying degrees in association with gene reactivation. In an effort to further examine the significance of 5-aza-CdRmediated cytosine and histone H3 K9 demethylation in the reversal of gene silencing, a more specific approach was sought. To this end, MDA-MB-231 cells were transfected with G9A-and DNMT1-specific siRNAs, alone and in combination, to see if re-expression of the epigenetically silenced MASPIN gene could be achieved in these cells solely by reducing the levels of key enzymes involved in cytosine methylation and H3 K9 dimethylation. UACC 1179 cells were not included in this analysis since they are not efficiently transfectable. By treating MDA-MB-231 breast tumor cells with siRNA duplexes targeting G9A and/or DNMT1 transcripts (either alone or in combination), we were able to reduce their expression levels by B80-90%, as detected by RT-PCR 4 days post-transfection (Figure 7a ). Following single transfections with either G9A or DNMT1 siRNA alone, RT-PCR analyses after 4 days revealed the presence of elevated MASPIN transcripts in MDA-MB-231 cells (Figure 7b ). When G9a and DNMT1 siRNAs were co-transfected, we saw an even larger increase in MASPIN expression to levels that were more than additive, indicating that both enzymes work cooperatively in the silencing of this gene and are necessary for maximal repression (Figure 7b ). In total, these data demonstrate that depletion of the enzymes largely responsible for cytosine methylation and/or histone H3 K9 di-methylation is sufficient for reactivation of these genes and also bolsters the idea that 5-azaCdR works via inhibition of G9A and/or DNMT1 to induce the reactivation of epigentically silenced tumor suppressor genes in human cancer.
Discussion
The inappropriate silencing of the antimetastatic, tumor suppressor genes DSC3 and MASPIN in breast epithelial tumor cells has been previously linked to DNA hypermethylation and histone hypoacetylation of their promoters (Domann et al., 2000; Oshiro et al., 2003; Oshiro et al., 2005) . In the present study, we also report elevated levels of transcriptionally repressive histone H3 K9 di-methylation in the 5 regions of these genes in the human breast cancer cell lines MDA-MB-231 and UACC 1179. Further experiments revealed that 5-aza-CdR-mediated reactivation of DSC3 and MASPIN in these cells is tightly associated with its ability to consistently decrease promoter H3 K9 di-methylation levels, even when DNA methylation was not reduced in these same regions. Moreover, the ability of 5-aza-CdR to reduce H3 K9 di-methylation in breast tumor cells is not limited to specific loci, as we have also shown global decreases in this histone modification following treatment. Next, we determined that 5-azaCdR appears to induce H3 K9 demethylation by mediating dose-dependent, post-transcriptional reductions in cellular G9A histone methyltransferase levels, suggesting an additional mode of action for this drug that is independent of its DNA-hypomethylating effects. Finally, targeted depletion of DNMT1 and G9A by siRNA led to increases in MASPIN expression that were supra-additive, further supporting the notion that multiple layers of epigenetic repression are at work in the aberrant silencing of tumor suppressor genes in human cancers. The ability of 5-aza-CdR to act as an inhibitor of DNA methylation is well documented (Christman, 2002; Karpf and Jones, 2002) ; however, our present results suggest that additional mechanisms of 5-aza-CdRmediated gene reactivation also exist. We conducted extensive sodium bisulfite sequencing of the DSC3 and MASPIN promoters in MDA-MB-231 and UACC 1179 breast tumor cells (94 clones each) to definitively quantitate total CpG methylation levels across each promoter before and after treatment with 5-aza-CdR. Statistical comparisons of promoter DNA methylation levels revealed that only the DSC3 promoter in MDA-MB-231 cells experienced significant demethylation (P-value p0.05) following 5-aza-CdR treatment, despite the ability of this drug to induce global DNA hypomethylation in both of our tumor cell lines. Interestingly, DSC3 in these cells also experienced the greatest level of drug-induced re-expression. Although these examples verify the importance of DNA methylation in transcriptional silencing and further support the DNA-hypomethylating ability of 5-aza-CdR, we also saw consistent reactivation of DSC3 and MASPIN in both cell strains even in the absence of significant local DNA demethylation. In addition to our findings, earlier evidence of DNA-methylation-independent mechanisms of action for this drug come from reports of 5-aza-CdRmediated induction of genes with unmethylated 5 0 CpG islands (Soengas et al., 2001; Zhu et al., 2001; Scott et al., 2006) , and gene activation in an organism lacking DNA methylation by its ribose analog, 5-aza-CR (Tamame et al., 1983 (Tamame et al., , 1988 . It has been postulated that the upregulation of such genes by 5-aza-CdR may be a result of its ability to induce DNA damage, with subsequent activation of upstream transcriptional initiators, such as p53. While DSC3 and MASPIN are p53-responsive genes, this explanation is unlikely in our case, as both of our breast tumor cell lines express mutant forms of the p53 protein. Furthermore, neither gene was reactivated in MDA-MB-231 cells following treatment with the DNA-damaging agent and p53 activator, doxorubicin, over a wide range of doses (Supplementary Figure 3) . Thus, as CpG island demethylation and DNA damage do not appear to fully explain the ability of 5-aza-CdR to consistently reactivate DSC3 and MASPIN in our tumor cells, we sought to investigate other potential targets of this drug in the reversal of epigenetic silencing.
ChIPs revealed elevated levels of histone H3 K9 dimethylation in the DSC3 and MASPIN promoters of both our breast tumor cell lines. Importantly, the ability of 5-aza-CdR to reactivate expression of these genes tracked closely with reductions of this repressive histone modification in their promoter regions. These results are in agreement with previous reports of decreased H3 K9 di-methylation levels in other epigenetically silenced genes following 5-aza-CdR treatment (Fahrner et al., 2002; Nguyen et al., 2002; Coombes et al., 2003) . However, our observation that local H3 K9 methylation can be decreased in the absence of significant DNA demethylation is a novel finding, and suggests that these distinct layers of epigenetic repression maintain their independence following 5-aza-CdR treatment, as H3 K9 methylation is not passively lost due as a result of DNA demethylation. Additionally, despite the ability of the DNA and H3 K9 methylation machinery to recruit each other to the regulatory regions of repressed genes (Fuks et al., 2003a; Geiman et al., 2004) , the loss of H3 K9 methylation does not direct DNA hypomethylation. This independence may be explained by our observation that the enzymes responsible for DNA and H3 K9 dimethylation are inhibited by 5-aza-CdR in distinct ways, through irreversible binding/sequestration of DNMT(s) (Creusot et al., 1982) and drug-induced decreases in G9A protein levels, respectively. These findings are significant in that they demonstrate the ability of epigentically silenced genes to be reactivated by 5-azaCdR in spite of continued DNA hypermethylation, by an alternative, independent mechanism of action that mediates reductions in transcriptionally repressive histone H3 K9 di-methylation.
Our findings suggest that 5-aza-CdR acts on multiple targets of epigenetic control to reactivate DSC3 and MASPIN in breast tumor cells, initiating decreases in DNA and/or histone H3 K9 methylation. Therefore, we sought to more precisely investigate the roles of two of the main enzymes responsible for depositing these repressive epigenetic marks, DNMT1 and G9A. To this end, we utilized siRNA targeted against both DNMT1 and G9A, and found that dual knockdown of these enzymes led to greater reactivation of MASPIN than simply decreasing the levels of either methyltransferase alone. Similarly, the greatest levels of re-expression following 5-aza-CdR treatment occurred when DNA and H3 K9 methylation were concurrently decreased (DSC3 in MDA-MB-231 cells), furthering the idea that multiple layers of epigenetic repression participate in gene silencing. However, while H3 K9 di-methylation was consistently reduced in the DSC3 and MASPIN promoters following 5-aza-CdR treatment, DNA methylation was not. These results suggest that the ability of 5-aza-CdR to induce CpG demethylation in these genes is context-specific, and likely due to differences in the components (e.g. DNMTs) of the repression complexes present at each gene regulatory region in a given cell type, as well as the specificity of this drug for inhibiting each of the DNMT isoforms. Additionally, the status of the transcription factor complement present in the cell may be a factor. Ultimately, greater clarification of the cell type-and loci-specific effects of 5-aza-CdR will require the complimentary use of more targeted genetic approaches, such as siRNA or stable knockout of different combinations of epigenetic modifying enzymes to elucidate its precise functions in the reactivation of particular genes.
In summary, the work presented here indicates that 5-aza-CdR acts to reverse multiple levels of epigenetic repression present on both DNA and histones, locally and globally, to reactivate silenced genes. Nonetheless, our findings also suggest that a determination of the precise manner in which 5-aza-CdR relieves transcriptional repression will require a greater understanding of the loci-specific effects of this drug, with regard to its ability to demethylate both DNA and histone H3 K9 residues. In fact, it appears from our study that a significant mode of 5-aza-CdR-induced transcriptional reactivation of DSC3 and MASPIN in breast cancer cells is via reductions in G9A and H3 K9 di-methylation levels, and that concurrent DNA demethylation is not mandatory in all cases. However, we also demonstrate that decreasing both DNA and H3 K9 methylation results in greater levels of gene reactivation than reductions in H3 K9 methylation alone, indicating that pharmacologic strategies targeting an assortment of modifications involved in epigenetic silencing may prove more efficacious toward a complete reversal of repressive chromatin architectures. Thus, the development of novel inhibitors of G9A and/or H3 K9 methylation, along with rational approaches toward their use in combination therapies with other epigenetic modifying drugs, represent possibilities for the effective transcriptional reprogramming of tumor cells in a more targeted manner.
Materials and methods
Cell culture and 5-aza-CdR treatment Normal human mammary epithelial cells (HMECs) were acquired from Clonetics (Cambrex, Walkersville, MD, USA). Human foreskin fibroblasts (HFFs) were maintained and cultured by the Arizona Cancer Center Cell Culture Shared Service. The MDA-MB-231 breast cancer cell line was obtained from the American Type Culture Collection (Rockville, MD, USA). The early passage sporadic breast cancer cell line UACC 1179, derived from pleural effusion (Trent et al., 1993) , was developed and maintained at the Arizona Cancer Center Cell Culture Core Facility. HMEC cells were maintained in mammary epithelial growth media (Cell Applications, Inc., San Diego, CA, USA). MDA-MB-231 cells were maintained in RPMI 1640 containing 5% fetal bovine serum supplemented with 50 mg/ml Penicillin/Streptomycin and 292 mg/ml L-glutamine. UACC 1179 and HFF cells were maintained in M15 media containing 5% fetal bovine serum. All cell lines were grown in 95% air/5% CO 2 atmosphere at 371C.
For 5-aza-CdR treatments, cells were grown at low density in six-well plates or T-150 dishes and treated with the indicated dose of 5-aza-CdR (Sigma, St Louis, MO, USA) dissolved in 1 Â phosphate-buffered saline (PBS), on day 0 and also on day 2, for a total duration of 4 days. Media was changed immediately before drug addition on both day 0 and day 2. RNA, DNA, protein or ChIP lysates were isolated from each of the samples on day 4.
Nucleic acid isolation
Total RNA was isolated from cells using an RNeasy s mini kit (QIAGEN, Valencia, CA, USA), and genomic DNA was isolated using the QIAamp s DNA Blood Mini Kit (QIAGEN). RNA and DNA samples were quantitated by ultraviolet (UV) absorbance measurements at 260 nm.
RT-PCR analysis
For real-time RT-PCR analysis of DSC3, MASPIN, G9A, DNMT1 and GAPDH gene expression, a reverse transcription step was performed using TaqMan s Reverse Transcription Reagents (Roche Molecular Systems, Branchburg, NJ, USA), 125 ng of total RNA in a 50 ml reaction. The RT reaction was primed with random hexamers and incubated at 251C for 10 min followed by 481C for 30 min, 951C for 5 min and a chill at 41C. Each 25 ml PCR reaction consisted of 4 ml of cDNA added to 12.5 ml of TaqMan s Universal PCR Master Mix (Roche Molecular Systems), 1.25 ml of gene-specific primer/ probe mix (Assays-on-Demand, Applied Biosystems, Foster City, CA, USA) and 7.25 ml of PCR water. The PCR conditions were 951C for 10 min, followed by 40 cycles of 951C for 15 s alternating with 601C for 1 min. DSC3-, MASPIN-, G9A-, DNMT1-and GAPDH-specific PCR was performed and the data collected using the ABI Prism 7000 real-time sequence detection system (Applied Biosystems). Differences in target gene expression in our normal and tumor cell lines, before and after treatment/transfection were determined using the equation 2 DCt for normalized relative expression, or 2
DDCt to calculate the normalized expression of samples in relation to normal HMEC or untransfected control levels. For these calculations, the target gene C t value for each sample is subtracted from its corresponding GAPDH C t value for normalization (DC t value), followed by subtraction of the normalized HMEC or untransfected control C t values from the normalized C t values of our tumor cell lines before and after treatment/transfection to yield a DDC t value. This value was then inserted into the equation 2 DDCt and multiplied by 100 to yield % HMEC or untransfected control expression.
5
0 RACE analysis The basal and 5-aza-CdR-activated MASPIN transcriptional start site was determined via 5 0 RACE analysis, using Invitrogen's 5 0 RACE System for Rapid Amplification of cDNA Ends, Version 2.0 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Briefly, total RNA (0 or 3 mg) was reverse transcribed to convert the 5 0 end of the predicted MASPIN transcript (UCSC human genome assembly: May 2004) into cDNA, using a gene-specific primer. RNA was digested and removed from the newly created cDNA using S.N.A.P. column purification (Invitrogen). Purified cDNA was then subject to a 5 0 poly-dC-tailing reaction using terminal deoxynucleotidyl transferase and dCTP, followed by PCR amplification using Invitrogen's Abridged Anchor Primer (Invitrogen) and another gene-specific primer internal to that used for cDNA synthesis. PCR amplification was performed using 2.5 Â Eppendorf PCR MasterMix (Eppendorf Scientific, Westbury, NY, USA) and 5 ml dC-tailed cDNA in a 50 ml reaction, under the following conditions: 941C for 3 min, followed by 35 cycles of 941C for 1 min, 551C for 30 s, 721C for 1 min, and ending with a final extension of 721C for 5 min. 5 0 RACE PCR products were run on a 3% agarose gel for size determination and then cloned into a pGEM T-Easy vector (Promega, Madison, WI, USA) for propagation and sequencing analysis of the inserted PCR product. Gene-specific primer sequences are available upon request.
Sodium bisulfite genomic sequencing Genomic DNA (5 mg) was modified with sodium bisulfite under conditions previously described (Domann et al., 2000) , with minor adjustments. Following sodium bisulfite modification, the DNA was bound to QIAGEN DNeasy spin columns, followed by on-column desalting and desulfonation. Regions of the DSC3 and MASPIN promoters were amplified from the bisulfite-modified DNA by two rounds of PCR using nested primers specific to the bisulfite-modified sequences of the DSC3 and MASPIN CpG islands. Primer sequences are available upon request.
First-round PCR amplification was performed using 2.5 ml bisulfite-modified DNA in a 25 ml reaction, under the following conditions: 951C for 5 min followed by 35 cycles of 921C for 1 min, 561C for 3 min, 721C for 2 min, and ending with a final extension of 721C for 5 min. Second-round PCR amplification utilized 1% of the first round PCR product as the template for the second round of PCR and the same thermocycler conditions as the first round, except that the annealing temperature was raised to 581C.
The resultant PCR product was run on a 3% agarose gel, gel purified using a QIAquick s Gel Extraction Kit (QIAGEN), and cloned into a pCR s 2.1-TOPO s vector supplied with the TOPO TA Cloning Kit (Invitrogen), according to the manufacturer's instructions. The inserts of positive recombinants (from white colonies) were PCR-amplified using M13 primers and evaluated on a 1.5% agarose gel. For each sample, PCR-amplified inserts from 94 clones were chosen for further sequence analysis. The cycle-sequence reaction was carried out using Big Dye s Terminator v3.1 chemistry (Applied Biosystems) on an MJ Thermocycler (MJ Research, Inc., Watertown, MA, USA). These reactions were further processed by running a clean-up procedure with CleanSEQ beads (Agencourt Bioscience Corporation, Beverly, MA, USA) on a Biomek FX automated workstation (Beckman-Coulter, Inc., Fullerton, CA, USA). Finally, the products were sequenced on an Applied Biosystems 3730xl DNA Analyzer.
The methylation status of individual CpG sites was determined by comparison of the sequences obtained for each clone with the known DSC3 and MASPIN sequences. The total number of methylated CpGs at all sites in the amplified region for all clones analysed was summed and divided by the number of total CpG sites in all analysed clones for the entire region to yield a percent regional methylation for each gene. Only CpG sites with good quality, decipherable sequence data were included in this calculation. A two-sample test of proportions was then performed using STATA 8.0 (StataCorp. LP, College Station, TX, USA) to calculate a P-value to determine whether or not statistically significant differences in regional methylation existed between treated and untreated samples at the 95% confidence level for the DSC3 and MASPIN regions analysed in both MDA-MB-231 and UACC 1179 breast tumor cells.
ChIP assays
ChIPs using anti-H3 K9 di-methyl (Upstate Biotech, Lake Placid, NY, USA) were performed according to the manufacturer's instructions with slight modifications . Cells were rinsed in 1 Â Hank's balanced salt solution (HBSS) with 0.1% ethylenediaminetetraacetic acid (EDTA) and treated with 1% formaldehyde for 10 min at 371C to form DNA-protein crosslinks. The cells were rinsed in icecold 1 Â HBSS with 0.1% EDTA containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml aprotinin, 1 mg/ml pepstatin A), scraped and collected by centrifugation at 41C. Cells were then resuspended in PIPES buffer (5 mM PIPES (pH 8.0), 85 mM KCl, 0.5% NP-40) containing protease inhibitors, and incubated for 10 min on ice. Cells were collected by centrifugation and resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.1)) containing protease inhibitors and incubated on ice for 10 min. The DNA-protein complexes were sonicated to lengths between 500 and 1000 bp, as determined by gel electrophoresis. Samples were centrifuged at 14 000 r.p.m. at 41C to spin out cell debris; then the supernatant was diluted 10-fold with ChIP dilution buffer containing protease inhibitors. One-tenth of the sample was set aside for input control, and the remaining sample was pre-cleared with Protein A Sepharose (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Following pre-clearing, the samples were split into three parts: two of the three samples were incubated with the appropriate antibody (5 ml anti-di-methyl H3 K9 and 7.5 ml anti-acetyl H3), while the third sample was left as a minus Ab control. All samples were rotated overnight at 41C. The chromatin-antibody complexes were collected using Protein A Sepharose and then sequentially washed with the manufacturer's low-salt, high-salt and LiCl buffers, followed by two washes with Tris-EDTA.
The chromatin-antibody complexes were eluted and for all samples (including input DNA), DNA-protein crosslinks were reversed with 5 M NaCl at 651C for 4 h. All samples were treated with proteinase K, and genomic DNA was recovered and purified by phenol-chloroform extractions and ethanol precipitations. This DNA was then quantitated using a BioPhotometer (Eppendorf Scientific). PCR amplification was performed using Taqman primer/probes specific for the DSC3, MASPIN and GAPDH promoters. Primer/probe sequences designed by our lab and validated by Applied Biosystems are available upon request.
Real-time PCR was used to analyse ChIP DNA, using the ABI Prism 7000 sequence detector following PE Applied Biosystems' TaqMan s Universal PCR Master Mix protocol. Each 25 ml PCR reaction consisted of 10 ml of DNA (at 1 ng/ml) added to 12.5 ml of TaqMan s Universal PCR Master Mix (Roche Molecular Systems), 1.25 ml of gene promoter-specific primer/probe mix (Assays-by-Design, Applied Biosystems) and 1.25 ml of PCR water. The PCR conditions were 951C for 10 min, followed by 40 cycles of 951C for 15 s alternating with 601C for 1 min. DSC3-, MASPIN-and GAPDHpromoter-specific PCR was performed and the data collected using the ABI Prism 7000 real-time sequence detection system (Applied Biosystems).
For each experiment, the threshold bar was set within the linear range of PCR amplification. The resulting C t and Rn files were exported to Microsoft Excel for data and graphical analysis. Quantification was determined by applying the comparative C t method, as described in the ABI 7000 sequence detection user guide and others (Litt et al., 2001) . Briefly, the percent respective input was calculated by subtracting the C t value of the ChIP DNA sample from the C t value of its respective input fraction and using this value as the power that 2 is raised to (i.e. 2 CtðinputÞÀCtðChIPÞ ), followed by multiplication by 100.
Global analysis of 5-methylcytosine levels via LC-MS Genomic DNA (8 mg) isolated from MDA-MB-231 and UACC 1179 cells treated with 0 and 10 mM 5-aza-CdR was brought up to 50 ml in 1 mM EDTA and denatured at 991C for 10 min, followed by snap freezing on ice. To this denatured genomic DNA, 62 ml of 2 mM sodium acetate (pH 4.5), 10 ml of 0.1 mM zinc chloride and 8 ml of Nuclease P1 (1 U/ml) (Sigma) were added before incubation at 371C for 1 h to digest samples to 5 0 -mononucleotides. The mononucleotides were then dephosphorylated by adding 10 ml of 80 mM Tris and 10 ml of Shrimp Alkaline Phosphatase (0.1 U/ml) (Fermentas Inc., Hanover, MD, USA), followed by a 30 min incubation at 371C to yield mononucleosides.
Individual nucleosides were separated via high pressure liquid chromatography (HPLC), using an HP/Agilent 1050 pumping system (Hewlett Packard/Agilent Technologies, Germany) equipped with a Zorbax SB-C18, 5 mm, 2.1 Â 250 mm column (Agilent Technologies, Palo Alto, CA, USA), onto which 30 ml of each digested DNA sample was injected via an HP 1050 autosampler. The isocratic mobile phase consisted of 7 mM ammonium acetate pH 6.7/methanol (95:5 v/v) delivered at a flow rate of 0.3 ml/min for 60 min, which allowed for separation of all five nucleosides. UV detection was performed at 254 nm using an HP 1050 Variable Wavelength Detector (Hewlett Packard/Agilent). LC separation was coupled to MS analysis using a Finnigan MAT TSQ 7000 triple quadrupole mass spectrometer (ThermoElectron, San Jose, CA, USA). Briefly, analytes were ionized using electrospray ionization (ESI) at an ESI source spray voltage of þ 4.5 kV. Ions were introduced into the mass spectrometer through a heated metal capillary maintained at 2501C. Initial screening of the samples was performed in positive mode in the first quadrupole based on full MS measurements between 50 and 550 m/z only (Q1 MS mode). Following the Q1 MS scan, single ion monitoring (SIM) was performed. The center masses in SIM mode were as follows: 227.90 for dC, 455.00 for dC dimer, 241.90 for 5-methyl-dC, 267.88 for dG, 242.90 for dT and 252.00 for dA. Pure dC, dG, dT and dA obtained from Sigma were also used as external standards. As pure 5-methyldeoxycytidine is not commercially available to use as a standard, its identification in biological samples was achieved by MS/MS analysis using the parent mass of 241.90. MS/MS was performed using 10 eV of energy collision induced dissociation (CID), yielding 5-methylcytosine as the major fragment ion (m/z 126.19). Finally, the percentage of methylated cytosines in each sample was determined using the following ratio of MS peak areas: (methyl-dC/(methyldC þ dC)) Â 100.
Acid extraction of proteins and immunoblot analysis of modified histones
For analysis of global di-methyl H3 K9 levels, MDA-MB-231 and UACC 1179 cells were grown to near confluence in T-150 dishes and were washed with ice-cold PBS. Cells were then scraped from the plate in ice-cold PBS supplemented with 1 mM PMSF and pelleted by centrifugation at 200 g for 10 min at 41C. The cell pellet was resuspended in 5-10 volumes of lysis buffer (1.5 mM MgCl 2 , 10 mM KCl, 10 mM HEPES (pH 7.9)), supplemented with PMSF (1.5 mM) and DTT (0.5 mM). Hydrochloric acid was then added to the resuspended cells to a final concentration of 0.2 M and allowed to incubate on ice for 30 min, with periodic vortexing. Following cell lysis, samples were centrifuged at 11 000 g for 10 min at 41C and the acid-soluble supernatant fraction was retained, whereas the acid-insoluble pellet was discarded. Finally, using 10 000 MWCO Slide-A-Lyzer Dialysis Cassettes (Pierce, Rockford, IL, USA), the acid-soluble protein supernatant was dialysed against 200 ml 0.1 M acetic acid, twice for 2 h each, and then three times against 200 ml H 2 O for 1 h, 3 h and overnight, respectively.
For each protein sample, concentrations were determined using Bio-Rad Protein Assay dye reagent (Bio-Rad Laboratories, Hercules, CA, USA), and equal amounts of dialysed, acid-extracted protein (20 mg) were size-fractionated via sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis on a 15% Ready Gel Tris-HCL Gel (Bio-Rad Laboratories) and transferred to a PVDF membrane using 1 Â Towbin transfer buffer (190 mM glycine, 25 mM Tris base, 1.5 mM SDS, 10% methanol). The membrane was blocked overnight at 41C in 5% milk-phosphate-buffered saline with T (PBS-T) (5% nonfat milk, 140 mM NaCl, 3 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , 0.05% TWEEN 20). The blocked membrane was then incubated with either H3 K9 di-methyl (1:500; Upstate Biotech) or actin (1:2000; Sigma-Aldrich, St Louis, MO, USA) primary antibodies in 5% milk-PBS-T for 1 h at room temperature and then washed three times with PBS-T. This was followed by another 1 h room temperature incubation with the appropriate peroxidase-conjugated secondary antibody diluted 1:10 000 in 5% milk-PBS-T, donkey antirabbit (Amersham Pharmacia Biotech) for anti-H3 K9 dimethyl and goat anti-mouse (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for anti-actin. After three more washes in PBS-T, the blots were visualized via chemiluminescence using Amersham ECL detection reagents (Amersham Pharmacia Biotech) and Kodak BioMax XAR Film (Eastman Kodak Company, Rochester, NY, USA). Protein bands were quantitated via integrated optical density measurements on a Kodak Gel Logic 200 Imaging System (Eastman Kodak Company) and normalized to each sample's respective actin loading control density.
Standard whole-cell protein isolation and immunoblot analysis For analysis of global G9A levels, untreated and 5-aza-CdRtreated MDA-MB-231 and UACC 1179 cells were grown to near confluence in T-150 dishes and washed with ice-cold PBS. Cells were then scraped from the plate in ice-cold PBS supplemented with 1 mM PMSF, 10 mg/ml aprotinin and 25 mg/ml leupeptin, followed by centrifugation at 500 g for 5 min at 41C. The cell pellet was lysed in ice-cold RIPA buffer (1% NP-40, 0.25% Na-deoxycholate, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA) with protease inhibitors (same as above) and placed on ice for 15 min, with periodic vortexing. Lysed cells were then centrifuged at 14 000 r.p.m. for 10 min at 41C to remove cellular debris. Concentrations of whole-cell lysates were determined as described above.
Equal amounts of whole-cell protein (30 mg) were sizefractionated via SDS-polyacrylamide gel electrophoresis on a 4-15% Ready Gel Tris-HCL Gel (Bio-Rad Laboratories) and transferred to a PVDF membrane using 1 Â Transfer Buffer (40 mM glycine, 50 mM Tris base, 20% methanol). The membrane was blocked overnight as previously described, and was then incubated with either G9A (1:667; Upstate Biotech) or actin (1:2000; Sigma-Aldrich) primary antibodies in 5% milk-PBS-T for 1 h at room temperature, followed by three washes with PBS-T. This was followed by another 1 h room temperature incubation with the appropriate peroxidaseconjugated secondary antibody diluted 1:10 000 in 5% milk-PBS-T, donkey anti-rabbit (Amersham Pharmacia Biotech) for anti-G9A and goat anti-mouse (Santa Cruz Biotechnology) for anti-actin. Blots were visualized and quantitated as described above.
SiRNA transfections MDA-MB-231 cells were plated in six-well dishes and grown to B50% confluence. Cells were then transfected using Lipofectamine 2000 (5 ml for single and 10 ml for dual transfections) (Invitrogen) and 6 ml G9A(BAT8)_2 and/or DNMT1_1 siRNA duplexes (QIAGEN) in a total volume of 1 ml antibiotic-and serum-free RPMI 1640 for 5 h. Following transfection, 1 ml RPMI 1640 supplemented with 5% fetal bovine serum was added to each well. The following day, media were removed and cells were covered with 2 ml of complete media (RPMI 1640 containing 5% fetal bovine serum supplemented with 50 mg/ml Penicillin/Streptomycin and 292 mg/ml L-glutamine). At 3 three days post-transfection, the media were changed again and total RNA or protein was isolated a day later (4 days after initial transfection). Real-time RT-PCR was then performed to assess mRNA expression levels following siRNA transfection.
